Nls Pharmaceutics Ltd's ROA from the fourth quarter of 2025 to the fourth quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nls Pharmaceutics Ltd's ROA in the fourth quarter of 2025?
Nls Pharmaceutics Ltd recorded a cumulative net loss of $-17 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -139.28%.

However, within the Healthcare sector 889 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 5082.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2023) IV. Quarter
Y / Y Total Assets Change	75.08 %	834.27 %	259.25 %	519.79 %	32.56 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-17	-12	-12	-12	-12
Return On Assets (TTM)	-139.28 %	-113.85 %	-149.6 %	-212.43 %	-365.49 %
NLSP's Total Ranking	# 5082	#	#	#	# 7
Total Assets (TTM) in million	11	11	13	11	7
Seq. Total Assets Change	0 %	-14.19 %	16.54 %	75.08 %	433.62 %
Seq. Net Income Change	-	-	-	-	-

NLSP's 5 Years Annual ROA >> Back to NLSP Management Effectiveness >> Compare NLSP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 420
Sector	# 890
Overall	# 5036

Return On Assets Statistics
High	Average	Low
1026.93 %	-32.46 %	-659.14 %
(Dec 31 2024)		(Dec 31 2023)

Financial Statements
Nls Pharmaceutics Ltd's Assets	$ 11 million	NLSP's Balance sheet
Nls Pharmaceutics Ltd's Income	$ -17 million	Quarterly NLSP's Income Statement
NLSP's Income by Division		See NLSP's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	162.4 %	76.07 %	-80.08 %	132.15 %	207.46 %
Total Assets in million	17	7	4	19	8
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-17	9	-12	-16	-12
Annual Return On Assets	-96.78 %	141.86 %	-327.84 %	-88.52 %	-148.81 %

NLSP's 5 Years Annual ROA >> Back to NLSP Management Effectiveness >> Compare NLSP ROA to its Competitors

More Return On Assets Ratios
NLSP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NLSP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NLSP's Competitors
Subscribers only: Roa for Nls Pharmaceutics Ltd's Suppliers
Subscribers only: Return On Assets for NLSP's Customers

You may also want to know
NLSP's Roi	NLSP's Inventory Turnover Ratio	NLSP's Growth Rates	NLSP's Dividend Comparisons
	NLSP's Profitability Ratios	NLSP's Asset Turnover Ratio	NLSP's Dividend Growth
NLSP's Roe	NLSP's Valuation Ratios	NLSP's Financial Strength Ratios	NLSP's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-07-07T12:13:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.